This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

An expert discusses how recent updates to AUA, EAU and NCCN guidelines have cautiously shifted toward more bladder-sparing approaches for BCG-unresponsive patients, incorporating new FDA-approved ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

An expert discusses how high-cost gene therapies require evidence standards including Phase 3 trial data showing complete response rates and durability, real-world evidence and health economic ...

Mulugeta Gebregziabher, Ph.D., spoke with Managed Healthcare Executive ahead of his presentation at IAS 2025 in Kigali, Rwanda, about the risks posed by U.S. cuts to global HIV prevention funding.

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

At the IAS 2025 conference in Kigali, Rwanda, Banky Olatosi, M.P.H., M.S., Ph.D., of the University of South Carolina, shed ...

A class of drugs, MDM2 inhibitors, being studied as cancer therapeutics may accidentally damage the protective barriers in the brain and eyes, finds new research in mice.

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...